Dulaglutide vs Semaglutide: What the Research Shows
Dulaglutide and Semaglutide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Dulaglutide if…
- you want an FDA-approved product: Trulicity (dulaglutide) is labelled as an adjunct to diet and exercise to improve glycemic control in type 2 diabetes[12]
Consider Semaglutide if…
- you want an FDA-approved product: Wegovy (semaglutide) is labelled to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight plus a weight-related condition[11]
- you want kidney-outcomes data in type 2 diabetes: The risk of the primary kidney composite was 24% lower with semaglutide (331 vs 410 first events; hazard ratio 0.76).[14]
What they have in common
- In the SUSTAIN head-to-head trial, HbA1c fell by 1·8 points with semaglutide 1·0 mg vs 1·4 with dulaglutide 1·5 mg[10]
Spec comparison
Showing 8 of 10 fields where the two differ. Class, PCAC vote, Jul 2026 are the same or both unknown.
| Field | Dulaglutide | Semaglutide |
|---|---|---|
| Class | GLP-1 agonist | GLP-1 agonist |
| Also called | Trulicity | sema, Ozempic, Wegovy, Rybelsus, Wegovy pill |
| FDA status | FDA approved (Trulicity) | FDA approved (Ozempic, Wegovy, Rybelsus) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | No WADA record in our data | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | [half-life by route] | approximately 1 weeksubcutaneous · FDA label (Ozempic) |
| Evidence strength | [evidence grade] | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 |
| Human studies we summarised | [n] | 23 human (19 randomized or controlled) of 27 summarised |
| Typical study doses | [dose range] |
|
| Named in FDA warning letters, 2026 | Not in the letters we track | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
SUSTAIN-7 is the head-to-head, and what else it reports
SUSTAIN-7 randomised 1201 adults with type 2 diabetes to low or high doses of semaglutide or dulaglutide.[10]
The abstract concludes that semaglutide was superior to dulaglutide at both low and high doses for glycaemic control and weight, with a similar safety profile.[10]
Gastrointestinal disorders were the most common adverse event in SUSTAIN-7, occurring in 48% of patients on the higher dulaglutide dose, 44% on the higher semaglutide dose and 33% on the lower dulaglutide dose.[10]
Funding matters for reading it: SUSTAIN-7 was funded by Novo Nordisk, the maker of semaglutide.[10]
Label differences between Trulicity and Ozempic
Trulicity's label starts adults at 0.75 mg weekly.[12]
Its dose ladder goes higher than the doses used in SUSTAIN-7: the maximum recommended dose is 4.5 mg once weekly.[12]
Trulicity's label covers pediatric patients 10 years of age and older with type 2 diabetes, whereas Ozempic's indications are adult.[12]
Trulicity is supplied only as a single-dose pen in several strengths, from 0.75 mg/0.5 mL up to 4.5 mg/0.5 mL.[12]
The Trulicity label gives an elimination half-life of approximately 5 days.[12]
Ozempic's label gives a half-life of approximately 1 week, so semaglutide persists a little longer.[5]
Both labels carry a diabetic-retinopathy warning, and the Trulicity label also says it is not recommended in patients with severe gastroparesis.[12]
Common questions
Trulicity vs Ozempic: which lowers A1C more?
In the SUSTAIN-7 head-to-head, semaglutide was superior to dulaglutide for glycaemic control at both low and high doses.[10]
Does Trulicity cause weight loss like Ozempic?
SUSTAIN-7 was powered for bodyweight superiority and concluded semaglutide reduced bodyweight more than dulaglutide, though both are labelled for type 2 diabetes, not obesity.[10]
Can children take Trulicity?
The Trulicity label includes pediatric patients 10 years of age and older with type 2 diabetes.[12]
Sources
- 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 2FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 3Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 4World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 5These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 6Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 7Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 8Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 9PubMed search: (dulaglutide[tiab] OR Trulicity[tiab]) AND (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.The lancet. Diabetes & endocrinology · 2018PMID 29397376Accessed 2 Oct 2026
- 11WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 12TRULICITY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 13Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
- 14Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.The New England journal of medicine · 2024PMID 38785209Accessed 2 Oct 2026
Found an error? Report a correction.